Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers with poor prognosis and unfavorable clinicopathological characteristics. Until now, its prognostic value has never been studied in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4459962?pdf=render |
| _version_ | 1798043800620236800 |
|---|---|
| author | Kapo Saukkonen Jaana Hagström Harri Mustonen Anne Juuti Stig Nordling Christian Fermér Olle Nilsson Hanna Seppänen Caj Haglund |
| author_facet | Kapo Saukkonen Jaana Hagström Harri Mustonen Anne Juuti Stig Nordling Christian Fermér Olle Nilsson Hanna Seppänen Caj Haglund |
| author_sort | Kapo Saukkonen |
| collection | DOAJ |
| description | Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers with poor prognosis and unfavorable clinicopathological characteristics. Until now, its prognostic value has never been studied in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to investigate podocalyxin expression in PDAC by a novel monoclonal antibody and a commercially available polyclonal antibody.With tissue microarrays and immuno-histochemistry, podocalyxin expression evaluation involved 168 PDAC patients. The associations of the podocalyxin tumor expression with clinicopathological variables were explored by Fisher's exact test and the linear-by-linear test. Survival analyses were by Kaplan-Meier analysis and the Cox proportional hazard model.The polyclonal antibody revealed membranous podocalyxin expression in 73 (44.0%) specimens and the monoclonal antibody was highly expressed in 36 (21.8%) cases. Membranous expression by the polyclonal antibody was associated with T classification (p=0.045) and perineural invasion (p=0.005), and high expression by the mono-clonal antibody with poor differentiation (p=0.033). High podocalyxin expression associated significantly with higher risk of death from PDAC by both the polyclonal antibody (hazard ratio (HR) = 1.62; 95% confidence interval (CI) 1.12-2.33; p=0.01) and the monoclonal antibody (HR = 2.10, 95% CI 1.38-3.20; p<0.001). The results remained significant in multivariate analysis, adjusted for age, gender, stage, lymph node ratio (≥/< 20%), and perivascular invasion (respectively as HR = 2.03; 95% CI 1.32-3.13, p=0.001; and as HR = 2.36; 95% CI 1.47-3.80, p<0.001).We found podocalyxin to be an independent factor for poor prognosis in PDAC. To our knowledge, this is the first such report of its prognostic value. |
| first_indexed | 2024-04-11T22:54:04Z |
| format | Article |
| id | doaj.art-f4341d66181e4762ab24968d3b907cbb |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T22:54:04Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f4341d66181e4762ab24968d3b907cbb2022-12-22T03:58:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01106e012901210.1371/journal.pone.0129012Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.Kapo SaukkonenJaana HagströmHarri MustonenAnne JuutiStig NordlingChristian FermérOlle NilssonHanna SeppänenCaj HaglundPodocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers with poor prognosis and unfavorable clinicopathological characteristics. Until now, its prognostic value has never been studied in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to investigate podocalyxin expression in PDAC by a novel monoclonal antibody and a commercially available polyclonal antibody.With tissue microarrays and immuno-histochemistry, podocalyxin expression evaluation involved 168 PDAC patients. The associations of the podocalyxin tumor expression with clinicopathological variables were explored by Fisher's exact test and the linear-by-linear test. Survival analyses were by Kaplan-Meier analysis and the Cox proportional hazard model.The polyclonal antibody revealed membranous podocalyxin expression in 73 (44.0%) specimens and the monoclonal antibody was highly expressed in 36 (21.8%) cases. Membranous expression by the polyclonal antibody was associated with T classification (p=0.045) and perineural invasion (p=0.005), and high expression by the mono-clonal antibody with poor differentiation (p=0.033). High podocalyxin expression associated significantly with higher risk of death from PDAC by both the polyclonal antibody (hazard ratio (HR) = 1.62; 95% confidence interval (CI) 1.12-2.33; p=0.01) and the monoclonal antibody (HR = 2.10, 95% CI 1.38-3.20; p<0.001). The results remained significant in multivariate analysis, adjusted for age, gender, stage, lymph node ratio (≥/< 20%), and perivascular invasion (respectively as HR = 2.03; 95% CI 1.32-3.13, p=0.001; and as HR = 2.36; 95% CI 1.47-3.80, p<0.001).We found podocalyxin to be an independent factor for poor prognosis in PDAC. To our knowledge, this is the first such report of its prognostic value.http://europepmc.org/articles/PMC4459962?pdf=render |
| spellingShingle | Kapo Saukkonen Jaana Hagström Harri Mustonen Anne Juuti Stig Nordling Christian Fermér Olle Nilsson Hanna Seppänen Caj Haglund Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. PLoS ONE |
| title | Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. |
| title_full | Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. |
| title_fullStr | Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. |
| title_full_unstemmed | Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. |
| title_short | Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. |
| title_sort | podocalyxin is a marker of poor prognosis in pancreatic ductal adenocarcinoma |
| url | http://europepmc.org/articles/PMC4459962?pdf=render |
| work_keys_str_mv | AT kaposaukkonen podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma AT jaanahagstrom podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma AT harrimustonen podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma AT annejuuti podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma AT stignordling podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma AT christianfermer podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma AT ollenilsson podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma AT hannaseppanen podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma AT cajhaglund podocalyxinisamarkerofpoorprognosisinpancreaticductaladenocarcinoma |